JOP20190159B1 - توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية - Google Patents

توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية

Info

Publication number
JOP20190159B1
JOP20190159B1 JOP/2019/0159A JOP20190159A JOP20190159B1 JO P20190159 B1 JOP20190159 B1 JO P20190159B1 JO P20190159 A JOP20190159 A JO P20190159A JO P20190159 B1 JOP20190159 B1 JO P20190159B1
Authority
JO
Jordan
Prior art keywords
mcl
inhibitor
combination
pharmaceutical compositions
taxane compound
Prior art date
Application number
JOP/2019/0159A
Other languages
English (en)
Inventor
Dale Porter
Olivier Geneste
Maia Chanrion
Jane Visvader
Francois Vaillant
Guillaume Lessene
Geoffrey Lindeman
Ana Leticia Maragno
Elisabetta Marangoni
Delphine Merino
Ensar Halilovic
James Whittle
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Priority claimed from PCT/EP2018/050298 external-priority patent/WO2018127575A1/en
Publication of JOP20190159A1 publication Critical patent/JOP20190159A1/ar
Application granted granted Critical
Publication of JOP20190159B1 publication Critical patent/JOP20190159B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

يتعلق الاختراع الحالي بتوليفة تشتمل على مثبط MCL-1 ومركب taxane، وتركيباتها واستخداماتها.
JOP/2019/0159A 2017-01-06 2018-01-05 توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية JOP20190159B1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762443082P 2017-01-06 2017-01-06
EP17157779 2017-02-24
US201762527360P 2017-06-30 2017-06-30
PCT/EP2018/050298 WO2018127575A1 (en) 2017-01-06 2018-01-05 Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
JOP20190159A1 JOP20190159A1 (ar) 2019-06-25
JOP20190159B1 true JOP20190159B1 (ar) 2023-09-17

Family

ID=61007674

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0159A JOP20190159B1 (ar) 2017-01-06 2018-01-05 توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية

Country Status (21)

Country Link
US (1) US10765680B2 (ar)
EP (1) EP3565547B1 (ar)
JP (1) JP7179733B2 (ar)
KR (1) KR102576567B1 (ar)
CN (1) CN110381937A (ar)
AU (1) AU2018205735B2 (ar)
BR (1) BR112019013907A2 (ar)
CA (1) CA3049095C (ar)
CL (1) CL2019001859A1 (ar)
CO (1) CO2019007261A2 (ar)
CU (1) CU20190064A7 (ar)
ES (1) ES2975274T3 (ar)
GE (1) GEP20227372B (ar)
IL (1) IL267791B (ar)
JO (1) JOP20190159B1 (ar)
MA (1) MA47198A (ar)
MX (1) MX2019008109A (ar)
PH (1) PH12019501451A1 (ar)
RU (1) RU2763544C2 (ar)
UA (1) UA125142C2 (ar)
ZA (1) ZA201904280B (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119156A1 (es) * 2019-06-17 2021-11-24 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma
WO2024138096A2 (en) * 2022-12-22 2024-06-27 Biopurification, Llc Taxane formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100870314B1 (ko) * 2008-02-19 2008-11-25 고려대학교 산학협력단 암 치료용 핵산 의약 조성물
EP2684167B1 (en) * 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105311016A (zh) * 2014-07-24 2016-02-10 中国科学院大连化学物理研究所 一种抗细胞凋亡Mcl-1蛋白抑制剂及其应用
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2019026819A1 (ja) * 2017-08-02 2019-02-07 株式会社村田製作所 アクチュエータ

Also Published As

Publication number Publication date
KR102576567B1 (ko) 2023-09-07
RU2019123982A (ru) 2021-02-08
JOP20190159A1 (ar) 2019-06-25
JP2020503361A (ja) 2020-01-30
GEP20227372B (en) 2022-04-25
BR112019013907A2 (pt) 2020-02-04
IL267791A (en) 2019-09-26
EP3565547B1 (en) 2024-03-13
ES2975274T3 (es) 2024-07-04
RU2763544C2 (ru) 2021-12-30
PH12019501451A1 (en) 2020-06-01
KR102576567B9 (ko) 2023-12-15
KR20190103317A (ko) 2019-09-04
US20190336505A1 (en) 2019-11-07
CL2019001859A1 (es) 2019-11-15
EP3565547A1 (en) 2019-11-13
JP7179733B2 (ja) 2022-11-29
AU2018205735B2 (en) 2024-02-01
MA47198A (fr) 2019-11-13
CA3049095A1 (en) 2018-07-12
US10765680B2 (en) 2020-09-08
ZA201904280B (en) 2022-03-30
AU2018205735A1 (en) 2019-07-11
IL267791B (en) 2022-02-01
MX2019008109A (es) 2019-09-04
CA3049095C (en) 2022-01-25
CO2019007261A2 (es) 2019-07-31
UA125142C2 (uk) 2022-01-19
RU2019123982A3 (ar) 2021-03-25
CU20190064A7 (es) 2020-02-04
CN110381937A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
TW201613911A (en) Heterocyclic compounds and uses thereof
PH12016502255A1 (en) Combination
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MD3347360T2 (ro) Compuși utili pentru inhibarea ROR-gama-t
MX2018014813A (es) Composiciones antibacterianas.
JOP20180018A1 (ar) تركيبات صيدلية تتضمن مثبط jak
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
PH12019500121A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
PH12019501451A1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceuitcal compositions thereof
IL283105A (en) Combination of MCL-1 inhibitor and midostearoin, its uses and pharmaceutical preparations
TW201613898A (en) Benzofuran analogue as NS4B inhibitor
IN2014MU00859A (ar)
IN2013MU03421A (ar)
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
EA201991623A1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
MX2016012646A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
EA201990305A1 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции